European CHMP recommends approval of ofatumumab (Kesimpta) for treatment of active relapsing multiple sclerosis
Ofatumumab will be licensed for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features It is a fully human monoclonal antibody that targets a receptor called CD20 expressed on the B-cells.
Source:
European Medicines Agency
SPS commentary:
Ofatumumab will be licensed for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features It is a fully human monoclonal antibody that targets a receptor called CD20 expressed on the B-cells.